The parallel, randomized, placebo-controlled study was published inBMC Complimentary Medicine and Therapies.It was performed on 104 European participants. The researchers found that those taking AGE for 12 months experienced 8% less CAC progression compared to those taking a placebo. The study also found that AGE significantly lowered systolic blood pressure, and improved other cardiovascular risk factors.
This is the first study to show that Kyolic AGE effectively improves risk factors in both European and non-European populations, despite dietary differences and genetic variants that can influence cardiovascular disease, according to a press release on the topic.
Related: Kyolic AGE Can Reduce BP, Review Confirms Heart Health Customers Seek “Calm,” Survey Suggests Keys to a Healthy Heart
The study also developed an algorithm that can predict which patients will benefit most from AGE supplementation, the press release notes. The AGE Algorithm calculates the outcome of various treatments based on diet, lifestyle, and genetic makeup. Authors of the study found that the algorithm was able to predict the individual results of Kyolic supplementation with 80% precision for CAC progression and 74% precision for reducing blood pressure.“This the first study to show that Kyolic Aged Garlic Extract effectively improves a number of risk factors for cardiovascular disease, regardless of differences in diet, lifestyle, ethnicity, or genetic makeup,” says Jay Levy, Director of Sales for Wakunaga of America, the maker of Kyolic Aged Garlic Extract, in the press release. “Even more exciting is the development of an innovative algorithm that may prove to be an effective tool for customizing supplementation as part of a heart-healthy lifestyle.”
